Rheolytic thrombectomy: any role left?

The ‘no-reflow’ phenomenon is still an unsolved issue in the setting of primary revascularization in acute myocardial infarction, and is associated with increased mortality, increased infarct size and left ventricular remodeling. A specific approach to this problem includes prevention of atherothrombotic debris dislocation by the use of embolic protection and thrombectomy devices. We review the literature on the prevention of embolization during primary percutaneous coronary intervention, with both distal protection and thrombus aspiration devices. In particular, this review is focused on rheolytic thrombectomy, and includes published studies and ongoing trials. The available evidence of an improved outcome in selected high-risk patients warrants an adequately designed and powered randomized trial.

KEYWORDS: acute myocardial infarction n ischemic coronary disease n no-reflow n primary percutaneous coronary intervention n reperfusion n thrombectomy

Primary percutaneous coronary intervention (P-PCI) is the preferred treatment for myocardial infarction with ST-segment elevation (STEMI) and is effective in opening the infarct-related artery [1–3]. However, microvascular obstruction with diminished myocardial perfusion occurs in a large proportion of patients treated with P-PCI despite a patent epicardial vessel, and this event, known as the ‘no-reflow’ phenomenon [4], is associated with increased mortality, increased infarct size and left ventricular remodeling [5–11]. Presence of microvascular damage can be indirectly demonstrated with angiographic parameters such as thrombolysis in myocardial infarction (TIMI) flow grade or myocardial blush grade (MBG), and more precisely with imaging techniques such as contrast ultrasonography [12], MRI [13], myocardial scintigraphy [14] and Doppler flow-wire evaluation [15].

Various mechanisms are implicated in the genesis of the no-reflow phenomenon, such as endothelial dysfunction, plugging of small vessels, compression of small vessels by tissue edema, thrombus and debris dislocation [16]. It is a double-faced process that starts during the ischemic period and increases at the time of reperfusion. Sometimes no-reflow after P-PCI becomes clinically and electrocardiographically evident with persistence of chest pain and incomplete ST-segment elevation resolution (STR). During the ischemic phase, tissue injury induces the production of oxygen reactive species, intracellular calcium overload and microvascular compression by edema. After reperfusion, metabolic events and platelet plugging occur, and they can be further complicated by thrombus and plaque debris mechanical dislocation during P-PCI. In fact, macroscopic distal embolization may occur in up to 16% of patients undergoing P-PCI [17]. However, epicardial vessel flow can be apparently maintained by adenosine-induced hyperemia in the areas surrounding the infarct zone.

Modern therapy of STEMI has to involve control and prevention of microvascular damage mechanisms and distal embolization [18]. Various adjunctive pharmacological therapies have been clinically tested with limited clinical benefits [19–21]. Direct stenting without predilatation may decrease embolization and the incidence of the no-reflow phenomenon [22]. More specific approaches to the problem of embolization during P-PCI include thrombectomy by means of different techniques and the use of embolic protection devices [23–25].

Distal protection devices

Distal occlusive devices are designed to prevent distal embolization by complete blockage of the antegrade flow by inflation of a balloon distal to the occlusion, followed by aspiration. Distal filters are nonocclusive devices that are advanced in the closed position beyond the target lesion and then opened in order to capture atherothrombotic debris migrating to the distal myocardium during predilatation and stent deployment. Several distal protection devices, either distal...
occlusive devices or distal filter devices, have proved their beneficial effects in PCI of saphenous vein grafts (SVG) [26,27]. Several randomized trials have also been conducted in primary angioplasty with contradictory findings. In the Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) trial [28] with a distal occlusion device (Medtronic Percusurge, Inc., CA, USA), although atherothrombotic debris was found in 78% of patients, there were no benefits in terms of myocardial perfusion in the treatment arm, whereas infarct size was paradoxically increased with the device (Table 1). The Aspiration of Liberated Debris in Acute Myocardial Infarction with Guardwire Plus System (ASPARAGUS) trial [29] obtained similar findings in 341 patients randomized to GuardWire Plus (Percusurge; n = 173) or conventional primary angioplasty (n = 168). There were no device-related procedural complications in either trial.

Despite the promising results of a non-randomized pilot study conducted at our department [30] with a distal filter (FilterWire, EZ™, Boston Scientific, MA, USA), subsequent randomized trials failed to demonstrate a significant benefit with the use of distal filter devices in P-PCI. In the randomized Protection Devices in PCI Treatment of Myocardial Infarction for Salvage of Endangered Myocardium (PROMISE) trial [31] with FilterWire EZ no benefits were found in terms of myocardial reperfusion (evaluated by Doppler flow-wire) or infarct size (evaluated by MRI) in the device-treated arm.

In a meta-analysis of the randomized trials [32], De Luca demonstrated that distal protection devices were associated with a significant advantage in terms of final myocardial blush grade 3 (51.5 vs 42.2%; OR: 1.73; 95% CI: 1.09–2.75; p = 0.02), although no significant benefit in terms of 30-day mortality was observed (2.5 vs 2.6%; OR: 0.97; 95% CI: 0.64–1.46; p = 0.88). Safety of adjunctive devices was comparable to standard treatment, as there were no significant differences in procedure-related complications (0.6 vs 0%; OR: 5.15; 95% CI: 0.25–107.9; p = 0.29).

Table 1. Summary of the trials cited in the review.

<table>
<thead>
<tr>
<th>Study</th>
<th>Years of enrollment</th>
<th>n</th>
<th>Device and design</th>
<th>End points</th>
<th>Main results</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Distal protection devices</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMERALD</td>
<td>2002–2003</td>
<td>501</td>
<td>GuardWire Plus (n = 252) vs control (n = 249); multicenter RCT</td>
<td>STR; infarct size with TC⁹⁹m</td>
<td>STR (74.2 vs 71.3%; p = 0.34); infarct size (12.0 vs 9.5%; p = 0.15)</td>
<td>[28]</td>
</tr>
<tr>
<td>ASPARAGUS</td>
<td>2002–2003</td>
<td>341</td>
<td>GuardWire Plus (n = 173) vs control (n = 168); multicenter RCT</td>
<td>MBG 3; TIMI 3; complete STR</td>
<td>MBG 3 (25.2 vs 20.3%; p = ns); TIMI 3 (77 vs 78%; p = ns); STR (37.5 vs 34.3%; p = NS)</td>
<td>[29]</td>
</tr>
<tr>
<td>PROMISE</td>
<td>2004</td>
<td>200</td>
<td>FilterWire EZ™ (n = 100) vs control (n = 100); single-center RCT</td>
<td>MFV; infarct size with MRI</td>
<td>MFV (33 ± 16 vs 35 ± 20 cm/s; p = 0.53); infarct size (11.8 ± 9.3% vs 10.4 ± 9.4%; p = 0.33)</td>
<td>[31]</td>
</tr>
<tr>
<td><strong>Thrombectomy devices</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florence AngiJet</td>
<td>2002–2003</td>
<td>100</td>
<td>AngiJet (n = 50) vs control (n = 50); single-center RCT</td>
<td>STR; cTFC; infarct size with TC⁹⁹m</td>
<td>STR (90 vs 72%; p = 0.022); cTFC (18.2 ± 7.7 vs 22.5 ± 11.0; p = 0.032); infarct size (13.0 ± 11.6 vs 21.2 ± 18.0%; p = 0.010)</td>
<td>[43]</td>
</tr>
<tr>
<td>AiMI</td>
<td>2001–2004</td>
<td>480</td>
<td>AngiJet (n = 240) vs control (n = 240); multicenter RCT</td>
<td>Infarct size with TC⁹⁹m; STR; MBG 3; MACE</td>
<td>Infarct size (9.8 ± 10.9 vs 12.5 ± 12.13%; p = 0.03); STR (60 vs 68%; p = 0.14); MBG 3 (30.6 vs 36.8%; p = 0.30); MACE (6.7 vs 1.7%; p = 0.01)</td>
<td>[44]</td>
</tr>
<tr>
<td>TAPAS</td>
<td>2005–2006</td>
<td>1071</td>
<td>Export (n = 535) vs control (n = 536); single-center RCT</td>
<td>MBG 0–1; STR; C-death 1 year; MACE 1 year</td>
<td>MBG 0–1 (17.1 vs 26.3%; p &lt; 0.001); STR (56.6 vs 44.2%; p &lt; 0.001); C-death 1 year (3.6 vs 6.7%; p = 0.020); MACE 1 year (5.6 vs 9.9%; p = 0.099)</td>
<td>[45]</td>
</tr>
<tr>
<td>De Rosa et al.</td>
<td>2006</td>
<td>60</td>
<td>AngiJet (n = 30) vs control (n = 30); single-center, retrospective</td>
<td>TIMI 3; cTFC; MACE 1 year</td>
<td>TIMI 3 (93.3 vs 83.3%; p = 0.034); cTFC (22.37 vs 32.37; p = 0.0004); MACE 1 year (10 vs 30%; p = 0.026)</td>
<td>[47]</td>
</tr>
</tbody>
</table>

cTFC: Corrected thrombolysis in myocardial infarction frame count; MACE: Major adverse cardiac event; MBG: Myocardial blush grade; MFV: Maximal flow velocity; MTI: Magnetic resonance; NS: Not significant; RCT: Randomized, controlled trial; STR: ST-resolution; TC⁹⁹m: Technetium-⁹⁹m; TIMI: Thrombolysis in myocardial infarction flow grade.
Distal protection devices failed to repeat in the setting of P-PCI the favorable results obtained in the percutaneous treatment of SVGs. Some authors argued that PCI-induced embolic burden is approximately one order of magnitude smaller in STEMI, as compared with vein grafts (1.2 vs 16 mm³ on average) [33], while other authors found comparable embolic burdens [34]. First-generation filter-based devices might have pores that are too large (typically >100 μm) to effectively protect against microembolization. By means of histopathological analysis of the debris retrieved with a distal filter during P-PCI, we demonstrated that angiographic signs of high thrombus burden (cut-off coronary occlusion pattern or large intracoronary minus image) independently predicted the total debris volume [35].

**Thrombectomy devices**

Thrombectomy devices may not only prevent distal embolization and its metabolic effects on microcirculatory function, but also allow the operator to have a better visualization of the underlying atherosclerotic lesion. Several monorail devices are currently available, both manual and engine-operated. Manual devices consist of a catheter with a large lumen where negative pressure is applied through a simple luer-lock syringe. Mechanical devices are connected to a pressure pump that creates a vortex around the tip that fragments the thrombus and increases suction capability by the Venturi effect (rheolytic thrombectomy).

Over the last few years, several large randomized trials and a great number of small reports of local experiences have been published on thrombectomy during P-PCI [36–42]. The first study that tested the efficacy of rheolytic thrombectomy (RT) was the Florence-AngioJet [43], a single-center, randomized trial with AngioJet (Possis Medical, MN USA) (Table 1). The AngioJet system consists of a main unit with a high-pressure infusion pump driving saline solution into a 5 F rapid-exchange catheter. The latter consists of two lumina, a smaller one to run the saline distally, and a bigger one collecting aspirated material. Saline solution exits at the catheter’s tip through microholes oriented proximally and comes back into the collector lumen at approximately 500 km/h, thereby creating a 360° zone of depression around the tip by the Venturi effect, crumbling and aspirating the thrombus. A total of 100 patients with a first acute myocardial infarction (AMI) were enrolled; primary end points were STR, corrected TIMI frame count (cTFC), and infarct size assessed by technetium-99m (Tc⁹⁹m) sestamibi scintigraphy. Results demonstrated benefits of RT in terms of lower cTFC (18.2 ± 7.7 vs 22.5 ± 11.0; p = 0.032), higher incidence of early STR (90 vs 72%; p = 0.022) and smaller infarct size (13.0 ± 11.6% vs 21.2 ± 18.0%; p = 0.010). The 6-month clinical outcomes were similar in the two arms, with a mortality rate of 2% in both groups, no reinfarctions, and a target vessel revascularization rate of 14 versus 23%, P-PCI versus RT, respectively (p = 0.270). Florence-AngioJet demonstrated the safety and efficacy of RT in P-PCI avoiding pharmacological therapy bias, as nearly all patients received the same Hb/IIIa inhibitor treatment.

The AngioJet Rheolytic Thrombectomy In Patients Undergoing Primary Angioplasty for AMI (AiMI) study [44] was a prospective, multi-center trial that randomized 480 patients with STEMI from 31 contributing sites in the USA and Canada between 2001 and 2004 to receive treatment with RT with the AngioJet device as an adjunct to conventional PCI or conventional PCI alone. The primary end point of the study was final infarct size evaluated by Tc⁹⁹m sestamibi imaging at 14–28 days after procedure. Secondary end points were final TIMI flow grade 3, MBG 3, STR more than 70%, and the rate of major adverse cardiac events (MACE) at 1 month. The AiMI study failed to demonstrate any advantage of RT in terms of reduction in infarct size and incidence of final TIMI 3 grade flow; on the contrary, it showed a significantly higher MACE rate at 30-day follow-up with RT. As a matter of fact, as randomization was performed before angiography, intracoronary evident thrombosis was not required as an inclusion criterion.

Manual aspiration devices such as the Export aspiration catheter (Medtronic) have been tested with very positive results in the recent Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study (TAPAS) [45]. This was a single-center, prospective, randomized trial that enrolled a total of 1071 patients with randomization before diagnostic angiography. The primary end point was the frequency of postprocedural MBG 0 or 1, and occurred in 17.1% in the thrombus-aspiration group and in 26.3% in the conventional PCI group (p < 0.001). In addition, the authors observed an unexpected result regarding a significant gradient in the secondary end points of 30-day mortality and MACE rate in patients with a final MBG of 0 or 1, 2 and 3. Mortality was 5.2, 2.9 and 1.0%, respectively (p = 0.003), and the MACE rate was 14.1, 8.8 and 4.2%, respectively (p < 0.001). These findings were confirmed at
1-year follow-up; moreover, patients randomized to aspiration versus conventional PCI showed a significantly lower incidence of cardiac death (3.6 vs 6.7%; p = 0.020) and of the composite end point of death and nonfatal reinfarction (5.6 vs 9.9%; p = 0.009).

Matching the results of the AiMI and TAPAS trial is very hard. On the one hand we have a simple, practical, low-cost manual aspiration device, consisting of a relatively flexible and nontraumatic catheter connected to a manual syringe, that showed improvement in terms of myocardial perfusion and 1-year mortality. On the other hand, there is a complex, expensive, high-pressure pump, with a stiffer catheter, that showed no benefits in terms of reperfusion, infarct size and a higher risk of MACE.

**Why are we still talking about rheolytic thrombectomy?**

In a Bayesian meta-analysis published in 2008, Grines et al. collected 125 publications, including randomized clinical trials (RCT), all reporting short-term mortality and postprocedural TIMI 3 flow, that enrolled 25,094 subjects with AMI treated with or without RT [46]. The AngioJet experience included 11 studies (two RCT and nine non-RCT) and 1018 patients. The authors concluded that short-term mortality, MACE rate and postprocedural TIMI 3 flow were similar between groups, although the RT group consisted of higher risk patients, with greater thrombus burden, longer symptom-to-balloon time and with a higher proportion of rescue PCI. Interestingly, RT was associated with reduced risk of mortality and increased postprocedural TIMI 3 flow with respect to standard PCI in the subgroup of patients undergoing rescue PCI after failed thrombolysis. However, this meta-analysis highlighted the lack of evidence in favor of RT as an adjunct to primary PCI, with a significant impact on the clinical practice of interventional cardiologists all over the world.

In the AiMI trial most operators were probably not ‘skilled’ in the use of AngioJet; in fact, AiMI was started before the Florence-AngioJet study, but was published later due to slow enrollment in a complex protocol that took 36 months to collect 480 patients from 31 centers. If we look at procedural data, we find a total procedural time significantly longer in the RT group (75.4 ± 30.9 vs 59.2 ± 26.8 min; p < 0.001), probably contributing to a larger infarct size. Furthermore, the device was not activated from proximal to distal to the culprit lesion, but was advanced distally to the lesion before turning on the pump, probably favoring distal embolization. In our experience with AngioJet, we did not experience distal embolization by activating the pump immediately proximal to the lesion and then advancing it in repeated passages. In addition, in the AiMI trial, temporary pacing before PCI was recommended in patients randomized to RT, because of the risk of device-induced asystole. However, more recent studies describe a high rate of AngioJet-induced bradycardia only in right coronary or dominant circumflex STEMI [47]. In our experience, the latest low-profile version of the RT catheter may cause brief episodes of asystole caused by adenosine release that vanishes in a few seconds and can be solved by asking the patient to cough.

AiMI authors interrogated themselves as to whether randomization after angiography could have introduced a selection bias against enrolling high-risk patients with a large amount of angiographically apparent thrombus. As a matter of fact, the proportion of patients with a totally occluded infarct-related artery was low in both groups, and baseline TIMI 3 flow was more frequent in the control arm (26 vs 19%; p < 0.05). While RT provided no benefit in reducing final infarct size in the overall population, there were differences in specific subsets of patients, in particular those with large thrombus burden. A total of 96 patients (50 treated with adjunct RT and 46 treated with PCI alone) had large or moderate baseline thrombus by angiographic analysis. In this patient subset, mean final infarct size was 10.8% in the RT group versus 8.1% in the PCI-alone group (p = 0.23). In this high thrombus burden group, however, the authors did not include patients with a totally occluded artery with an abrupt cut-off.

In a study focused on the use of drug-eluting stents (DES) and bare-metal stents (BMS) in patients with acute coronary syndromes, Sianos et al. reported the 2-year clinical outcome and the predictors of stent thrombosis of the infarct-related artery (IRA) [48]. The authors proposed a new thrombus grading in two categories based on the TIMI 14 trial classification [49], considering as ‘small thrombus burden’ a thrombus less than grade 4, and ‘large thrombus burden’ for thrombus grade 4, with grade 4 being defined as definite thrombus, with the largest dimension more than two vessel diameters. In patients presenting with an occluded infarct-related artery (thrombus grade 5), thrombus burden was reclassified into one of the two categories after flow achievement with either guidewire crossing or a small deflated balloon passage or dilatation.
Such simple classification of thrombus burden allowed accurate stratification of the risk of stent thrombosis of the IRA.

Intracoronary thrombus appears to be strictly connected to stent underexpansion and malapposition [50], as established by intravascular ultrasound. This condition is one of the strongest predictors of early and late stent thrombosis, both for BMS [51] and DES [52]. Primary stenting during AMI has been recognized as an independent predictor of late stent malapposition both after BMS and DES with an incidence two- to three-fold higher compared with elective stenting [53-54]. Sianos reported a 2-year cumulative IRA stent thrombosis rate significantly higher in large versus small thrombus burden patients (16 vs six events). Large thrombus burden appeared as the most hazardous independent predictor of stent thrombosis of the IRA. Among patients with large thrombus burden, those treated with RT had a significantly lower 2-year stent thrombosis rate versus patients not receiving RT (0 vs 11.3%; p < 0.001). The authors concluded that the controversial results of trials involving RT were probably connected to underestimation of importance of thrombus burden, and called for prospective randomized exploration of the potential benefits of thrombectomy devices in high-risk STEMI patients, such as those with large thrombus burden.

Recently De Rosa et al. retrospectively analyzed 60 patients (two groups of 30 consecutive patients) with large thrombus burden defined according to the definitions of the TIMI3 trial: 30 patients were treated with standard P-PCI, and 30 received RT prior to P-PCI [47]. Angiographic analysis showed benefits of RT in terms of final TIMI 3 flow (93.3 vs 83.3%; p = 0.034), and of final cTFC (22.4 vs 32.4; p = 0.0004). The MACE rate at 1-year follow-up was significantly lower in the RT group (10 vs 30%; p = 0.026), as well as all-cause mortality (3.3 vs 13.3%; p < 0.001) and cardiac mortality (3.3 vs 10.0%; p = 0.007).

### Rheolytic thrombectomy: our experience

In the Cath Laboratory of the Cardiothoracic and Vascular Department of the University of Pisa, Italy, RT with the AngioJet system has been in use since 2004. Among patients treated with P-PCI within 12 h from symptom onset from August 2004 to October 2007, we retrospectively identified a subgroup of 198 patients with large thrombus burden at angiography, according to Sianos’ classification cited above. A total of 53 of these patients received AngioJet thrombectomy, while 145 did not. Baseline clinical profile was similar between the groups, but a higher rate of rescue P-PCI after failed thrombolysis (21 vs 9%; p = 0.03) appeared in the thrombectomy group. No device-related complications were reported and there was no need for temporary pacing. There was no difference regarding final TIMI 3 flow while final MBG grade 3 was more frequent in the RT group (28 vs 8%; p = 0.003) (Table 2). Moreover, although visual estimation of lesion length after crossing with the guidewire was similar between groups (15 ± 6 vs 16 ± 8 mm; p > 0.2), total length of stent implanted was significantly shorter in the RT group (14 ± 9 vs 19 ± 7 mm; p = 0.0004). In our opinion, clearing the lesion from adherent thrombus by means of RT allowed the operators to choose shorter stents, as they felt more comfortable with precise stent positioning. At 1-year follow-up, RT was associated with a significantly higher freedom from the composite end point of cardiovascular death, re-infarction and target lesion revascularization (94.6 vs 81.3%; p = 0.047).

These encouraging findings, presented orally in 2009 [55], prompted us to design a multicenter prospective randomized trial to verify whether RT in patients with large thrombus burden may positively affect infarct size and clinical outcome. The Efficacy of Rheolytic Thrombectomy in Patients With High Thrombus Burden During Primary PCI trial started in June 2008 and will enroll 200 STEMI patients presenting within

| Table 2. Procedural and 1-year results of primary percutaneous coronary intervention with and without AngioJet thrombectomy at our center. |
|---------------------------------|-----------------|-----------------|----------|
| Lesion length (mm)              | 15 ± 6          | 16 ± 8          | >0.2     |
| Stent length (mm)               | 19 ± 7          | 14 ± 9          | 0.0004   |
| Final thrombolysis in myocardial infarction 3 flow (%) | 84              | 89              | >0.2     |
| Final myocardial blush grade 3 flow (%)       | 8               | 28              | 0.003    |
| Composite of death/reinfarction/target lesion revascularization | 18 (18.9%)     | 2 (5.3%)        | 0.047    |

P-PCI: Primary percutaneous coronary intervention.
Conclusion & future perspective

Distal embolization of atherothrombotic debris occurs quite frequently during primary PCI and has a relevant impact on clinical outcome. Both pharmacological and mechanical adjunctive treatments have been tested in the clinical arena, with mixed results. At present, two important points are still to be clarified: which patients benefit from the use of adjunctive devices for thrombus management and how can they be identified by clinical and angiographic characteristics; and which kind of device has the best safety and efficacy profile, and which is also cost effective? A growing body of evidence supports the concept that patients with STEMI and large fresh thrombus burden may benefit from thrombectomy on top of pharmacological treatment during primary PCI; however, this evidence comes mainly from retrospective analysis and no consistent data are emerging from strong randomized trials. The scientific community calls for clinical trials in order to build evidence-based medicine. However, prospective randomized trials sometimes offer more questions than answers, particularly when trial design is cumbersome, enrollment is slow, patient selection is biased and operator experience with the investigational device is low. On the other hand, single-center studies are often biased by inadequate study design and power, and by conflicts of interest, as pointed out in a recent meta-analysis of the trials involving adjunctive devices to prevent distal embolization during STEMI [58]. Single-center or multicenter design appeared to be the only variable significantly related to different clinical outcome, as an increase by one in the number of centers increased the risk of incomplete STR by 1.4% (95% CI: 0.48–2.28), and the risk of final impaired MBG by 1% (95% CI: 0.02–1.97%). Although the authors of this meta-analysis conclude that the use of thrombectomy devices cannot be recommended based on the results

12 h from symptom onset with an angiographic finding of large thrombus burden according to Sianos’ classification. The primary end points are STR at 60 min after the end of PCI, and infarct size evaluated by means of MRI with delayed enhancement technique at 3 months [56,57]. The secondary end points are final TIMI 3 flow, cTFC and MBG, and freedom from the composite end point of cardiovascular death, reinfarction and target lesion revascularization at 1 year. A substudy within the trial features coronary optical coherence tomography at 1 year to evaluate stent endothelization, malapposition and thrombosis in a high-risk subset of patients suffering from diabetes, chronic kidney disease and coronary multivessel disease.

Executive summary

Introduction
* Goals of modern therapy for acute myocardial infarction involve prevention of microvascular damage and of distal embolization, as well as prevention of the ‘no-reflow’ phenomenon. For this purpose, pharmacological approaches and adjunctive devices have been developed.

Distal protection devices
* First-generation distal protection devices failed to reproduce the excellent results obtained in saphenous vein graft intervention in the setting of primary percutaneous coronary intervention (PCI).

Thrombectomy devices
* Both manual and mechanical devices are available. The thrombectomy literature includes several large randomized trials and a great number of small reports of local experiences. One large multicenter study reported negative results with rheolytic thrombectomy, while a large single-center trial on manual aspiration demonstrated a significant improvement in myocardial reperfusion as well as a reduction in 1-year cardiac mortality versus conventional primary PCI.

Why are we still talking about rheolytic thrombectomy?
* Several small experiences confirm the safety and efficacy of rheolytic thrombectomy, especially in high-risk patients with large thrombus burden at angiography. Furthermore, the negative results of the AngioJet Rheolytic Thrombectomy In Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction trial were probably determined by patient selection bias and limited operator experience with the AngioJet device.

Rheolytic thrombectomy: our experience
* In a retrospective analysis of our experience with AngioJet in primary PCI we found positive results in terms of improved myocardial reperfusion and better outcome at 1 year versus conventional PCI. These findings prompted us to design a multicenter, prospective, randomized trial in ST-segment elevation patients with large thrombus burden, to evaluate the impact of rheolytic thrombectomy on infarct size assessed by means of cardiac magnetic resonance imaging.

Conclusion & future prospective
* Rheolytic thrombectomy may still play an important role in primary PCI in high-risk patients with large thrombus burden at initial angiography. An adequately powered randomized trial will hopefully prove this concept.
of single-center studies, in our opinion those operators who are familiar with a specific device and who experience a benefit from its use should not abandon thrombectomy on the basis of a multicenter trial with many flaws. An adequately powered, well-designed, multicenter trial performed by skilled operators will contribute to the search for a definitive answer on thrombectomy in the setting of P-PCI.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Bibliography

Papers of special note have been highlighted as:
* of interest
** of considerable interest


* Randomized, controlled trial (RCT) fails to prove infarct reduction with distal balloon protection during primary percutaneous coronary intervention (PCI).


* RCT fails to prove infarct reduction with filter-based distal protection during primary PCI.


* Single-center registry proving usefulness of rheolytic thrombectomy in case of large thrombus burden.


* Single-center trial proving infarct reduction with rheolytic thrombectomy in primary PCI.


* RCT failing to prove clinical benefit of rheolytic thrombectomy in primary PCI.


* Large RCT proving reduction in mortality with thrombectomy in primary PCI.


* Single-center registry demonstrating the clinical benefit of rheolytic thrombectomy during primary PCI in case of large thrombus burden.


* Single-center registry suggesting the role of thrombotic burden in favoring DES thrombosis after primary PCI.


59 Meta-analysis suggesting that single-center studies may be biased towards more positive findings.